SARS-CoV-2 3’-5’ Exonuclease Antibody #99098
- WB
Supporting Data
| REACTIVITY | Vir |
| SENSITIVITY | Endogenous |
| MW (kDa) | 60 |
| SOURCE | Rabbit |
Application Key:
- WB-Western Blotting
Species Cross-Reactivity Key:
- Vir-Virus
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
Storage
Protocol
Specificity / Sensitivity
Species Reactivity:
Source / Purification
Background
SARS-CoV-2 3’-5’ exonuclease, or ExoN, is a non-structural protein (Nsp14) translated from ORF1b (2). It is a proofreading enzyme that functions in the replicase holoenzyme to read, excise, and repair errors in the newly transcribed viral RNA (3). RNA viruses generally have a high mutation rate and Coronaviridae, and others among the Nidovirales genus, have the largest and most complex genomes of RNA viruses (4). The 3’-5’ exonuclease is highly conserved between Coronaviruses, suggesting it’s important to the maintenance of such a large genome (5). The 3’-5’ exonuclease also provides a functionality to the RNA capping process, alongside the 2’-ribose methyl transferase (Nsp14), the helicase (Nsp13), and a guanylyl transferase (6,7). It is, however, the exonuclease function that is the key challenge to antiviral drug design with nucleoside analogue approaches (8).
- Zhou, P. et al. (2020) Nature 579, 270-273.
- Tortorici, M.A. and Veesler, D. (2019) Adv Virus Res 105, 93-116.
- Minskaia, E. et al. (2006) Proc Natl Acad Sci U S A 103, 5108-13.
- Saberi, A. et al. (2018) PLoS Pathog 14, e1007314.
- Denison, M.R. et al. RNA Biol 8, 270-9.
- Chen, Y. and Guo, D. (2016) Virol Sin 31, 3-11.
- Ma, Y. et al. (2015) Proc Natl Acad Sci U S A 112, 9436-41.
- Shannon, A. et al. (2020) Antiviral Res 178, 104793.
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.